Why the study?
End-stage heart failure patients post-cardiogenic shock who cannot be weaned from dobutamine present a management challenge, making home dobutamine a potential solution.
What are the outcomes, safety, and predictors of survival for continuous home intravenous dobutamine infusion in dobutamine-dependent end-stage heart failure patients?
What are the outcomes, safety, and predictors of survival for continuous home intravenous dobutamine infusion in dobutamine-dependent end-stage heart failure patients?
Home dobutamine infusion in dobutamine-dependent end-stage heart failure patients allows for a 32% one-year survival, with GFR >60 mL/min and BNP <1000 ng/L serving as strong predictors of survival to help identify appropriate candidates.
No takes yet. Share an insight, caveat, or question.
Home dobutamine may be feasible in select end-stage HF; leaves open efficacy, safety, and selection criteria for randomized evaluation.
Jobbé‐Duval et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: